TY - JOUR
T1 - Effects of taurocholic acid metabolism by gut bacteria
T2 - A controlled feeding trial in adult African American subjects at elevated risk for colorectal cancer
AU - Wolf, Patricia G.
AU - Gaskins, H. Rex
AU - Ridlon, Jason M.
AU - Freels, Sally
AU - Hamm, Alyshia
AU - Goldberg, Sarah
AU - Petrilli, Phyllis
AU - Schering, Teresa
AU - Vergis, Sevasti
AU - Gomez-Perez, Sandra
AU - Yazici, Cemal
AU - Braunschweig, Carol
AU - Mutlu, Ece
AU - Tussing-Humphreys, Lisa
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2020/9
Y1 - 2020/9
N2 - Colorectal cancer (CRC) is the third leading cause of cancer and second leading cause of cancer death in the United States. Recent evidence has linked a high fat and animal protein diet and microbial metabolism of host bile acids as environmental risk factors for CRC development. We hypothesize that the primary bile salt taurocholic acid (TCA) is a key, diet-controlled metabolite whose use by bacteria yields a carcinogen and tumor-promoter, respectively. The work is motivated by our published data indicating hydrogen sulfide (H2S) and secondary bile acid production by colonic bacteria, serve as environmental insults contributing to CRC risk. The central aim of this study is to test whether a diet high in animal protein and saturated fat increases abundance of bacteria that generate H2S and pro-inflammatory secondary bile acids in African Americans (AAs) at high risk for CRC. Our prospective, randomized, crossover feeding trial will examine two microbial mechanisms by which an animal-based diet may support the growth of TCA metabolizing bacteria. Each subject will receive two diets in a crossover design― an animal-based diet, rich in taurine and saturated fat, and a plant-based diet, low in taurine and saturated fat. A mediation model will be used to determine the extent to which diet (independent variable) and mucosal markers of CRC risk and DNA damage (dependent variables) are explained by colonic bacteria and their functions (mediator variables). This research will generate novel information targeted to develop effective dietary interventions that may reduce the unequal CRC burden in AAs.
AB - Colorectal cancer (CRC) is the third leading cause of cancer and second leading cause of cancer death in the United States. Recent evidence has linked a high fat and animal protein diet and microbial metabolism of host bile acids as environmental risk factors for CRC development. We hypothesize that the primary bile salt taurocholic acid (TCA) is a key, diet-controlled metabolite whose use by bacteria yields a carcinogen and tumor-promoter, respectively. The work is motivated by our published data indicating hydrogen sulfide (H2S) and secondary bile acid production by colonic bacteria, serve as environmental insults contributing to CRC risk. The central aim of this study is to test whether a diet high in animal protein and saturated fat increases abundance of bacteria that generate H2S and pro-inflammatory secondary bile acids in African Americans (AAs) at high risk for CRC. Our prospective, randomized, crossover feeding trial will examine two microbial mechanisms by which an animal-based diet may support the growth of TCA metabolizing bacteria. Each subject will receive two diets in a crossover design― an animal-based diet, rich in taurine and saturated fat, and a plant-based diet, low in taurine and saturated fat. A mediation model will be used to determine the extent to which diet (independent variable) and mucosal markers of CRC risk and DNA damage (dependent variables) are explained by colonic bacteria and their functions (mediator variables). This research will generate novel information targeted to develop effective dietary interventions that may reduce the unequal CRC burden in AAs.
KW - Colon cancer disparities
KW - Colorectal cancer
KW - H2S
KW - Microbial sulfur metabolism
KW - Prospective randomized crossover feeding trial
UR - http://www.scopus.com/inward/record.url?scp=85087769906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087769906&partnerID=8YFLogxK
U2 - 10.1016/j.conctc.2020.100611
DO - 10.1016/j.conctc.2020.100611
M3 - Article
C2 - 32695922
AN - SCOPUS:85087769906
SN - 2451-8654
VL - 19
JO - Contemporary Clinical Trials Communications
JF - Contemporary Clinical Trials Communications
M1 - 100611
ER -